Status:
COMPLETED
FIRMAGON® Intensive Drug Monitoring
Lead Sponsor:
Ferring Pharmaceuticals
Conditions:
Prostate Cancer
Eligibility:
MALE
18+ years
Brief Summary
To evaluate the safety profile of FIRMAGON® (to fulfill the regulatory authority's requirement of Intensive Drug Monitoring in Chinese participants with prostate cancer need androgen deprivation thera...
Eligibility Criteria
Inclusion
- Diagnosed with prostate cancer and in need of ADT
- Decision made to prescribe FIRMAGON® prior to enrollment
- Willingness and ability to provide written informed consent
- The participants are taking the marketed drug FIRMAGON®
Exclusion
- Not signed informed consent
- Any participants who are unsuitable to participate in this study because of any other reasons will not be qualified to participate in this study.
Key Trial Info
Start Date :
August 20 2019
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
December 31 2022
Estimated Enrollment :
1454 Patients enrolled
Trial Details
Trial ID
NCT05181800
Start Date
August 20 2019
End Date
December 31 2022
Last Update
September 27 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
China Primary Healthcare Foundation
Beijing, China